S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
Canadian autoworkers ratify new labor agreement with Ford
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A coal mine fire in southern China's Guizhou province kills 16 people
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Forecast, Price & News

$2.52
-0.01 (-0.40%)
(As of 09/22/2023 ET)
Compare
Today's Range
$2.51
$2.65
50-Day Range
$2.52
$8.03
52-Week Range
$2.50
$15.00
Volume
12,076 shs
Average Volume
34,232 shs
Market Capitalization
$3.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADIL stock logo

About Adial Pharmaceuticals (NASDAQ:ADIL) Stock

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Price History

ADIL Stock News Headlines

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
Adial Pharmaceuticals reports Q2 results
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Company Calendar

Last Earnings
8/21/2023
Today
9/24/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-12,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.17 per share

Miscellaneous

Free Float
960,000
Market Cap
$3.07 million
Optionable
Not Optionable
Beta
1.03
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Cary John Claiborne MBA (Age 62)
    CEO, Pres & Director
    Comp: $415.08k
  • Mr. Joseph A. M. Truluck M.B.A. (Age 45)
    MBA, CFO, Treasurer & Sec.
    Comp: $279.7k
  • Dr. Bankole A. Johnson DSc (Age 63)
    FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer
  • Mr. John R. Martin J.D.
    Gen. Counsel
  • Mr. Alex Lugovoy
    Chief Bus. Officer
  • Dr. Jack W. Reich Ph.D. (Age 74)
    Head of Regulatory
  • Mr. Mark H. Peikin
    Chief Strategy Officer & Chief Devel. Officer
  • Mr. Lawrence Goldman CPA (Age 67)
    Controller
  • Ms. Catherine Fratila
    Controller













ADIL Stock - Frequently Asked Questions

Should I buy or sell Adial Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADIL shares.
View ADIL analyst ratings
or view top-rated stocks.

How have ADIL shares performed in 2023?

Adial Pharmaceuticals' stock was trading at $5.3750 at the start of the year. Since then, ADIL stock has decreased by 53.1% and is now trading at $2.52.
View the best growth stocks for 2023 here
.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a decline in short interest in August. As of August 31st, there was short interest totaling 64,600 shares, a decline of 12.6% from the August 15th total of 73,900 shares. Based on an average daily trading volume, of 131,100 shares, the days-to-cover ratio is presently 0.5 days. Approximately 6.2% of the shares of the stock are short sold.
View Adial Pharmaceuticals' Short Interest
.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ADIL earnings forecast
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its earnings results on Monday, August, 21st. The company reported ($1.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.17.

When did Adial Pharmaceuticals' stock split?

Adial Pharmaceuticals's stock reverse split before market open on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Adial Pharmaceuticals own?
When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.20%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman and William B Stilley III.
View institutional ownership trends
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.52.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals (NASDAQ:ADIL) has a market capitalization of $3.07 million. The company earns $-12,730,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The official website for the company is www.adialpharma.com. The company can be reached via phone at (434) 422-9800 or via email at investor_relations@haynesintl.com.

This page (NASDAQ:ADIL) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -